Unia Europejska - słoweński - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dislipidemije - sredstva za spreminjanje lipidov - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Unia Europejska - słoweński - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurija, paroksizmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Unia Europejska - słoweński - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriaza - imunosupresivi - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Unia Europejska - słoweński - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidno slikanje - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Unia Europejska - słoweński - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 0,4 mg / 1 tableta - buprenorfin

Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 0,4 mg / 1 tableta - buprenorfin

Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 2 mg / 1 tableta - buprenorfin

Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 2 mg / 1 tableta - buprenorfin

Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin